OHR Pharmaceutical Inc.

Financials

v3.10.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2018
Sep. 30, 2018
CURRENT ASSETS    
Cash $ 3,110,441 $ 3,750,436
Prepaid expenses and other current assets 103,269 247,998
Total Current Assets 3,213,710 3,998,434
EQUIPMENT, net 13,421 15,763
OTHER ASSETS    
Intangible assets, net 7,446,891 7,611,918
TOTAL ASSETS 10,674,022 11,626,115
CURRENT LIABILITIES    
Accounts payable and accrued expenses 597,152 651,781
Notes payable 73,217
Total Current Liabilities 597,152 724,998
TOTAL LIABILITIES 597,152 724,998
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 2,829,248 and 2,829,248 shares issued and outstanding, respectively 283 283
Additional paid-in capital 132,299,718 132,226,341
Accumulated deficit (122,223,131) (121,325,507)
Total Stockholders' Equity 10,076,870 10,901,117
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 10,674,022 $ 11,626,115
v3.10.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2018
Dec. 31, 2017
OPERATING EXPENSES    
General and administrative $ 680,995 $ 1,510,032
Research and development 58,021 2,387,731
Depreciation and amortization 167,370 284,986
OPERATING LOSS 906,386 4,182,749
OTHER INCOME (EXPENSE)    
Interest income 8,762 31,391
Total Other Income (Expense) 8,762 31,391
LOSS FROM OPERATIONS BEFORE INCOME TAXES (897,624) (4,151,358)
NET LOSS $ (897,624) $ (4,151,358)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.32) $ (1.48)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:    
BASIC AND DILUTED (in shares) 2,829,248 2,810,189
v3.10.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2018
Dec. 31, 2017
OPERATING ACTIVITIES    
Net loss $ (897,624) $ (4,151,358)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 135,701
Stock option and warrant expense 73,377 629,286
Depreciation 2,342 2,867
Amortization of intangible assets 165,027 282,118
Changes in operating assets and liabilities    
Prepaid expenses and other current assets 144,729 134,799
Accounts payable and accrued expenses (54,629) (1,229,054)
Net Cash Used in Operating Activities (566,778) (4,195,641)
FINANCING ACTIVITIES    
Proceeds from warrants exercised for cash 225,000
Repayments of short-term notes payable (73,217) (106,387)
Net Cash Provided by/(Used in) Financing Activities (73,217) 118,613
NET CHANGE IN CASH (639,995) (4,077,028)
CASH AT BEGINNING OF PERIOD 3,750,436 12,801,085
CASH AT END OF PERIOD 3,110,441 8,724,057
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Interest $ 779 $ 1,770